Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Pembrolizumab (Mk-3475) In Patients With Advanced Renal Cell Cancer

Next Previous
X
Search
Trial Profile

A Phase 1b, Open Label, Dose Finding Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of Axitinib (Ag-013736) In Combination With Pembrolizumab (Mk-3475) In Patients With Advanced Renal Cell Cancer

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 12 May 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Axitinib (Primary) ; Pembrolizumab (Primary)
  • Indications Renal cell carcinoma
  • Focus Adverse reactions
  • Acronyms KEYNOTE-035
  • Sponsors Pfizer

    • Most Recent Events

    • 04 Jan 2021 Results (data cut-off date, 23rd July 2019)long-term efficacy and safety of the axitinib/pembrolizumab after 46-55 months from study initiation, published in the European Journal of Cancer
    • 18 Aug 2020 Results published in the Clinical Cancer Research.
    • 31 May 2020 Results assessing long-term efficacy and safety data of the combination AXI/pembro from the Phase 1 trial, with almost 5 years of follow-up, presented at the 56th Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top